With the expansion of Opdivo in the treatment paradigm, its sales are expected to grow globally to $361m by 2028 at a compound annual growth rate (CAGR) of 5.81%. Credit: Tada Images / ...

Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma (NHL), has long been deemed incurable: Though the disease responds well to initial treatment, oncologists tell ...

Osel Inc., a clinical-stage biopharma company pioneering live biotherapeutic products (LBPs), today announced a clinical trial agreement with SWOG Cancer Research Network for a pivotal Phase 3 ...

Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced publication of the findings from the randomized, phase III CALGB (Alliance ...

JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a >40% reduction in risk of death, whereas Signatera-negative patients ...

The FDA's priority review for Opdivo with AVD targets first-line treatment for stage 3 or 4 cHL in patients aged 12 and older. The phase 3 SWOG S1826 study supports the review, focusing on progression ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...

Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone ...

AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 ...

Celebrex improved DFS in ctDNA-positive colon cancer patients, reducing cancer recurrence and death risk by 37% compared to placebo. ctDNA status post-surgery was highly prognostic of DFS and OS, ...